Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on equity-55.2%+3.7pp-58.9%-6.9pp-52%-1.9pp-50.1%-1.1pp-49%
Return on assets-51.4%+3.3pp-54.7%-5.8pp-48.9%-1.5pp-47.4%-0.5pp-46.9%-10.2pp
Return on invested capital-75.6%+4.2pp-79.7%-183%
Liquidity
Current ratio14×+1.1×12.8×-2.1×14.9×+2.2×12.7×-1.6×14.3×+1.2×
Quick ratio14×+1.1×12.8×-2.1×14.9×+2.2×12.7×-1.6×14.3×+1.2×
Cash ratio2.5×+0.7×1.8×-3.5×5.2×-0.5×5.7×+1.9×3.8×-0.5×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×
Per Share
Book value per share$7.19-10.0%$7.99+9.8%$7.28+1.9%$7.14+19.5%$5.97-27.0%
Valuation
Market capitalization$1.02B+22.8%$830.58M+11.0%$748.5M-5.3%$790.65M+25.7%$628.96M-29.9%
Enterprise value$958.05M+22.0%$785.05M+23.5%$635.88M-6.2%$677.99M+17.0%$579.23M-29.7%
Price / book3.1×+0.4×2.7×+0.2×2.5×-0.7×3.2×+0.1×3.1×-0.4×
Earnings yield-14.2%+5.8pp-20%+0.2pp-20.2%-2.9pp-17.3%+2.9pp-20.3%-11.3pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do ArriVent BioPharma, Inc.'s ratios come from?
Every ratio is computed from ArriVent BioPharma, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.